Pixium Vision - ESGO financing deal shores up balance sheet
Pixium has entered into a convertible notes financing arrangement with US-based healthcare investor European Select Growth Opportunities Fund (ESGO), for up to €30m of notes redeemable in cash and/or in shares, without interest, for a period of up to 36 months. The first tranche of €5.5m (gross) in notes was received on 14 July, and Pixium expects the funding will enable it to maintain operations to the end of Q123. While the possibility of a conversion of note tranche(s) to shares would increase the number of shares outstanding, this arrangement provides funding stability, thus enabling Pixium to execute on its Prima development strategy, which we believe could reach EU market approval in H125.Pixium Vision SA is a company that specializes in sensorial neuromodulation. Co. is also collaborating with scientific groups and clinicians at research institutes and clinical centers around the world, including Stanford University (USA). Co. is developing and aims to commercialize Bionic Vision Systems (BVS) – namely active implantable medical devices to treat blindness caused by degeneration of photoreceptor cells in the retina.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.